Pediatric Neuroblastoma Treatment Market
Pediatric Neuroblastoma Treatment Market Study by Immunotherapy, Chemotherapy, and Others from 2023 to 2033
Analysis of Pediatric Neuroblastoma Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Pediatric Neuroblastoma Treatment Market Outlook (2023 to 2033)
The global pediatric neuroblastoma treatment market stands at a valuation of US$ 2.1 billion in 2023 and is predicted to exhibit expansion at a stellar 9.7% CAGR over the next ten years. As such, worldwide demand for pediatric neuroblastoma treatment is forecasted to rake in a revenue of US$ 5.3 billion by 2033-end.
Neuroblastoma is a common cancer that is often found in the adrenal glands that are located on top of kidneys and it is known to affect children of ages 5 or younger more often. Chemotherapy, radiotherapy, and stem cell transplantation are the most common types of treatment available for pediatric neuroblastoma.
The rising number of new cases of pediatric neuroblastoma and increasing investments in research and development of novel treatments for neuroblastoma are expected to primarily bolster market growth over the coming years.
- In March 2023, the University of Leeds and Leeds Children’s Hospital partnered to launch The Children’s Health Outcomes Research at Leeds (CHORAL) Research Centre. The five-year project will be focusing on childhood disorders such as cancers, mental issues, and other chronic diseases. The project has also received a total funding of around US$ 6.6 million from Leeds Hospital Charity, the University of Leeds, and Leeds Teaching Hospitals NHS Trust.
Increasing demand for drugs and therapeutics to treat neuroblastoma, the launch of government initiatives to promote awareness about neuroblastoma, and rising investments in healthcare infrastructure development around the world are other factors that could benefit the demand for pediatric neuroblastoma treatment in the future. The increasing number of new drug and treatment approvals from regulatory authorities is also slated to uplift market growth potential through 2033.
Contrastingly, the high costs associated with pediatric neuroblastoma treatment and growing awareness regarding the side effects of the same are anticipated to foil pediatric neuroblastoma treatment demand over the next ten years. Non-profit organizations are also taking initiative to provide affordable and effective treatment for neuroblastoma in children.
- The Isabella Santos Foundation based in North Carolina, United States, is helping people whose children are suffering from pediatric neuroblastoma by paying US$ 1500 for their treatment using precision medicine. The non-profit had helped around 81 kids by October 2022 and intends to help more in the future until insurance covers the cost of precision medicine.
Growing availability and launch of new and advanced cancer treatment alternatives are forecasted to open up new avenues for pediatric neuroblastoma treatment providers going forward.
Report Attributes |
Details |
|
Pediatric Neuroblastoma Treatment Market Size (2023) |
US$ 2.1 Billion |
|
Projected Market Value (2033F) |
US$ 5.3 Billion |
|
Global Market Growth Rate (2023 to 2033) |
9.7% CAGR |
|
Growth Rate of Immunotherapy Segment (2023 to 2033) |
10% CAGR |
|
Growth Rate of Chemotherapy Segment (2023 to 2033) |
9.5% CAGR |
|
Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Will New Companies be Able to Make a Difference in the Market for Pediatric Neuroblastoma Treatment?
“Start-ups Focusing on Capital Raise and Product Approvals to Advance Business Potential”
Aspiring companies providing pediatric neuroblastoma treatment are raising new funds to expand their research and business scope on a global level.
- In June 2022, Ariceum Therapeutics, a start-up known for its radiopharmaceutical products, announced the completion of its Series A funding round as it raised around US$ 26.3 million. EQT Life Sciences, HealthCap, and Pureos Bioventures were involved in the financing round. The company intended to use the funds to advance the research and development of satoreotide, which could be used in the treatment of neuroblastoma, neuroendocrine tumors, etc.
Pediatric neuroblastoma treatment start-ups can also benefit from accelerator programs and other supportive initiatives that allow them to scale their business models with adequate support from established authorities or companies in the marketplace. Companies are also expected to focus on the development of pediatric leukemia treatment, pediatric lymphoma treatment, and treatment of other health conditions affecting children.
- In January 2021, KidsX, an international consortium of pediatric hospitals focused on improving digital health, announced that it had selected 13 start-up companies to be a part of its accelerator program.
More new developments by start-ups and how they augment product standards and pricing trends have been explained in this latest pediatric neuroblastoma treatment market research study by Fact.MR, a market research and competitive intelligence provider.
Country-wise Insights
How Will Pediatric Neuroblastoma Treatment Demand Fare in Japan?
“Increasing Investments in Healthcare Infrastructure Development Favoring Market Growth”
Demand for pediatric neuroblastoma treatment in Japan is estimated to be primarily driven by increasing focus on healthcare infrastructure development and rising investments in medical R&D. Growing awareness regarding neuroblastoma, increasing spending on health and fitness, growing availability of novel cancer treatments, and rising number of cases of pediatric neuroblastoma are other factors that could augment market development in Japan over the next ten years.
- In October 2022, Kyushu University, a national university located in Fukuoka, Japan, sponsored a new clinical trial to assess the safety of GAIA-102 and decide on a dose for Phase II. The trial was titled ‘Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas or Malignant Pediatric Solid Tumors With Lung Metastases’.
Declining birth rates and a rapidly increasing geriatric population are anticipated to have a hindering effect on demand for pediatric neuroblastoma treatment in Japan across the forecast period and beyond.
Will European Countries be Remunerative Markets in This Space?
“Rising Awareness Regarding Neuroblastoma to Bolster Market Development”
The prevalence of various types of cancers has increased in European countries, which has led to the launch of several new awareness initiatives to educate people about different types of cancers. Increasing investments in cancer R&D, rising focus on healthcare infrastructure development, and increasing incidence of pediatric neuroblastoma are other factors that could promote demand for pediatric neuroblastoma treatment in European countries such as Germany, the United Kingdom, France, etc.
- As per statistics provided on the Cancer Research UK website, around 100 children between the ages of 0 to 14 years are diagnosed with neuroblastoma in the United Kingdom.
Increasing popularity of precision medicine and the growing availability of new treatments for pediatric neuroblastoma in Europe are also projected to create new opportunities for pediatric neuroblastoma treatment providers in Europe.
Which Country Leads Pediatric Neuroblastoma Treatment Demand in North America?
“Favorable Reimbursement Policies in United States Offering Moneymaking Opportunities”
The United States is known for its developed healthcare infrastructure and favorable reimbursement scenario, both of which are anticipated to uplift pediatric neuroblastoma treatment demand over the coming years. Increasing incidence of different types of cancer, rapid adoption of novel cancer treatments, and rising investments in medical research and development are also expected to favor market growth in the future.
- As per statistics listed on the American Cancer Society website, nearly 700 to 800 new cases of neuroblastoma are recorded in the United States every year. At the time of diagnosis, the average age of children was found to be 1 or 2 years.
An increasing number of new treatment launches and product approvals in the country are also estimated to offer lucrative growth scope for pediatric neuroblastoma treatment companies across the forecast period.
- In June 2022, Omblastys (omburtamab) was granted a priority review for a Biologics License Application by the Food and Drug Administration (FDA) of the United States. The drug was intended to be used for the treatment of children affected by leptomeningeal metastasis caused by neuroblastoma.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Category-wise Insights
Which Therapy is Primarily Used for the Treatment of Neuroblastoma?
“Chemotherapy Universally Used as Primary Treatment Option”
Based on therapy type, the market for pediatric neuroblastoma treatment is segmented into chemotherapy, immunotherapy, and others.
Chemotherapy has been the popular and preferred type of treatment for most types of cancer and this is true in the case of neuroblastoma as well. Chemotherapy is used to cushion the impact of harmful symptoms and control the spread of cancer. This treatment is also used in conjunction with other treatments to improve its effectiveness and enable faster recovery for patients.
Rising investments in research and development of new chemotherapy solutions and increasing efficacy of chemotherapy procedures for pediatric neuroblastoma treatment are also expected to bolster market growth going forward.
- Demand for chemotherapy in pediatric neuroblastoma treatment is anticipated to rise at 9.5% CAGR over the next ten years.
A more comprehensive account of all industry-governing aspects such as local supply, global demand, etc., has been mentioned exclusively in this Fact.MR research report.
Competitive Landscape
Prime pediatric neuroblastoma treatment providers are focusing on increasing awareness about neuroblastoma through the launch of new educational initiatives that also allow them to reach out to potential new patients.
- In August 2021, United Therapeutics, an American biotechnology company, announced that it had partnered with former NFL player Devon Still and his daughter Leah to launch the educational initiative called ‘Braving NeuroBLASToma’. The initiative intended to educate people more about cancer affecting immature nerve cells known as neuroblasts.
Top pediatric neuroblastoma treatment providers are also hastening the launch of new products by fast-tracking their clinical trials and winning new approvals from regulatory authorities.
- In March 2023, Aptorum Group Limited, a pharmaceutical organization headquartered in the United Kingdom, announced the completion of the end of Phase 1 (EOP1) meeting with the United States Food and Drug Administration (FDA) for SACT-1, which is a repurposed drug targeting neuroblastoma.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Pediatric Neuroblastoma Treatment Industry Research Segmentation
-
By Therapy Type :
- Immunotherapy
- Chemotherapy
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
-
By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Table of Content
1. Preface 1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Market 4. Market Overview 4.1. Introduction 4.1.1. Market Definition 4.1.2. Industry Evolution / Developments 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Market Analysis and Forecast, 2023–2033 4.4.1. Market Revenue Projections (US$ Mn) 4.5. Porter’s Five Force Analysis 5. Market Outlook 5.1. Epidemiology Pediatric Neuroblastoma 5.2. Pipeline Analysis 5.3. Key Unmet Needs in the Market 5.4. Global Market: Rate of Metastasis in Neuroblastoma 5.5. Global Market: Neuroblastoma Relapse/Refractory cases 5.6. Rate of Utilization of MIBG-131 6. Global Market Analysis and Forecast, by Therapy Type 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast, by Therapy Type, 2023–2033 6.3.1. Immunotherapy 6.3.2. Chemotherapy 6.3.3. Others 6.4. Market Attractiveness, by Therapy Type 7. Global Market Analysis and Forecast, by End-user 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast, by Distribution Channel, 2023–2033 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies & Drug Stores 7.4. Market Attractiveness, by Distribution Channel 8. Global Market Analysis and Forecast, by Region 8.1. Key Findings 8.2. Market Value Forecast, by Region 8.2.1. North America 8.2.2. Europe 8.2.3. Rest of the World 8.3. Market Attractiveness, by Region 9. North America Market Analysis and Forecast 9.1. Introduction 9.1.1. Key Findings 9.2. Market Value Forecast, by Therapy Type, 2023–2033 9.2.1. Immunotherapy 9.2.2. Chemotherapy 9.2.3. Others 9.3. Market Value Forecast, by Distribution Channel, 2023–2033 9.3.1. Hospital Pharmacies 9.3.2. Retail Pharmacies & Drug Stores 9.4. Market Value Forecast, by Country, 2023–2033 9.4.1. U.S. 9.4.2. Canada 9.5. Market Attractiveness Analysis 9.5.1. By Therapy Type 9.5.2. By Distribution Channel 9.5.3. By Country 10. Europe Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. Market Value Forecast, by Therapy Type, 2023–2033 10.2.1. Immunotherapy 10.2.2. Chemotherapy 10.2.3. Others 10.3. Market Value Forecast, by Distribution Channel, 2023–2033 10.3.1. Hospital Pharmacies 10.3.2. Retail Pharmacies & Drug Stores 10.4. Market Value Forecast, by Country/Sub-region, 2023–2033 10.4.1. Germany 10.4.2. U.K. 10.4.3. France 10.4.4. Rest of Europe 10.5. Market Attractiveness Analysis 10.5.1. By Therapy Type 10.5.2. By Distribution Channel 10.5.3. By Country/Sub-region 11. Rest of the World Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Therapy Type, 2023–2033 11.2.1. Immunotherapy 11.2.2. Chemotherapy 11.2.3. Others 11.3. Market Value Forecast, by Distribution Channel, 2023–2033 11.3.1. Hospital Pharmacies 11.3.2. Retail Pharmacies & Drug Stores 11.4. Market Attractiveness Analysis 11.4.1. By Therapy Type 11.4.2. By Distribution Channel 12. Company Profiles 12.1. United Therapeutics Corporation 12.1.1. Company Overview (HQ, Business Segments, Employee Strength) 12.1.2. Product Portfolio 12.1.3. SWOT Analysis 12.1.4. Financial Overview 12.1.5. Strategic Overview 12.2. APEIRON Biologics AG 12.2.1. Company Overview (HQ, Business Segments, Employee Strength) 12.2.2. Product Portfolio 12.2.3. SWOT Analysis 12.2.4. Financial Overview 12.2.5. Strategic Overview 12.3. Baxter 12.3.1. Company Overview (HQ, Business Segments, Employee Strength) 12.3.2. Product Portfolio 12.3.3. SWOT Analysis 12.3.4. Financial Overview 12.3.5. Strategic Overview 12.4. Cellectar Biosciences, Inc. 12.4.1. Company Overview (HQ, Business Segments, Employee Strength) 12.4.2. Product Portfolio 12.4.3. SWOT Analysis 12.4.4. Financial Overview 12.4.5. Strategic Overview 12.5. Pfizer, Inc. 12.5.1. Company Overview (HQ, Business Segments, Employee Strength) 12.5.2. Product Portfolio 12.5.3. SWOT Analysis 12.5.4. Financial Overview 12.5.5. Strategic Overview 12.6. MacroGenics, Inc. 12.6.1. Company Overview (HQ, Business Segments, Employee Strength) 12.6.2. Product Portfolio 12.6.3. SWOT Analysis 12.6.4. Financial Overview 12.6.5. Strategic Overview 12.7. Bayer AG 12.7.1. Company Overview (HQ, Business Segments, Employee Strength) 12.7.2. Product Portfolio 12.7.3. SWOT Analysis 12.7.4. Financial Overview 12.7.5. Strategic Overview
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: List of acronyms used in the report
Table 02: Global Market: Pipeline Analysis
Table 03: Global Market: Pipeline Analysis
Table 04: Global Market: Pipeline Analysis
Table 05: Global Market: Pipeline Analysis
Table 06: Global Market: Pipeline Analysis
Table 07: Global Market: Pipeline Analysis
Table 08: Global Market: Pipeline Analysis
Table 09: Global Market: Pipeline Analysis
Table 10: Global Market: Pipeline Analysis
Table 11: Global Market: Pipeline Analysis
Table 12: Global Market: Pipeline Analysis
Table 13: Global Market: Pipeline Analysis
Table 14: Global Market: Pipeline Analysis
Table 15: Global Market Value (US$ Mn) Forecast, by Therapy Type, 2023–2033
Table 16: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 17: Global Market Value (US$ Mn) Forecast, by Region, 2023–2033
Table 18: North America Market Value (US$ Mn) Forecast, by Country, 2023–2033
Table 19: North America Market Value (US$ Mn) Forecast, by Therapy Type, 2023–2033
Table 20: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 21: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 22: Europe Market Value (US$ Mn) Forecast, by Therapy Type, 2023–2033
Table 23: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 24: Rest of the World Market Value (US$ Mn) Forecast, by Therapy Type, 2023–2033
Table 25: Rest of the World Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market
Figure 02: Global Market Size (US$ Mn), by Therapy Type, 2022
Figure 03: Global Market Segments with Leading Market Share (%), 2022
Figure 04: Global Market Value (US$ Mn) Forecast, 2023–2033
Figure 05: Global Market Value Share (%), by Therapy Type, 2022
Figure 06: Global Market Value Share (%), by Distribution Channel, 2022
Figure 07: Global Market Value Share (%), by Region, 2022
Figure 08: Key Industry Events
Figure 09: Porter’s Five Forces Analysis
Figure 10: Epidemiology of Neuroblastoma
Figure 11: Epidemiology of Neuroblastoma: Numbers of Annual New Neuroblastoma Cases in Key Markets
Figure 12: Epidemiology of Neuroblastoma Key Research Findings
Figure 13: Epidemiology of Neuroblastoma, by Country
Figure 14: Epidemiology of Neuroblastoma, by Country
Figure 15: Epidemiology of Neuroblastoma, by Country
Figure 16: Key Unmet Needs in the Market
Figure 17: Global Market: Rate of Metastasis to the Brain
Figure 18: Global Market: Rate of Metastasis to the Brain
Figure 19: Global Market: Neuroblastoma Relapse/Refractory cases
Figure 20: Global Market: Neuroblastoma Relapse/Refractory cases
Figure 21: Global Market: Utilization of MIBG-131
Figure 22: Global Market: Utilization of MIBG-131
Figure 23: Global Market Value Share (%), by Therapy Type, 2023 and 2033
Figure 24: Global Market Attractiveness, by Therapy Type, 2023–2033
Figure 25: Global Market Revenue (US$ Mn) Forecast, by Immunotherapy, 2023–2033
Figure 26: Global Market Revenue (US$ Mn) Forecast, by Chemotherapy, 2023–2033
Figure 27: Global Market Revenue (US$ Mn) Forecast, by Others, 2023–2033
Figure 28: Global Market Value Share (%), by Distribution Channel, 2023 and 2033
Figure 29: Global Market Attractiveness, by Distribution Channel, 2023–2033
Figure 30: Global Market Revenue (US$ Mn) Forecast, by Hospital Pharmacies, 2023–2033
Figure 31: Global Market Revenue (US$ Mn) Forecast, by Retail Pharmacies &Drug Stores, 2023–2033
Figure 32: Global Market Value Share (%), by Region, 2023 and 2033
Figure 33: Global Market Attractiveness, by Region, 2023–2033
Figure 34: North America Market Revenue (US$ Mn) forecast, 2023–2033
Figure 35: North America Market Value Share (%), by Country, 2023 and 2033
Figure 36: North America Market Attractiveness, by Country, 2023–2033
Figure 37: North America Market Value Share (%), by Therapy Type, 2023 and 2033
Figure 38: North America Market Attractiveness, by Therapy Type, 2023–2033
Figure 39: North America Market Value Share (%), by Distribution Channel, 2023 and 2033
Figure 40: North America Market Attractiveness, by Distribution Channel, 2023–2033
Figure 41: Europe Market Revenue (US$ Mn) Forecast, 2023–2033
Figure 42: Europe Market Value Share (%), by Country/Sub-region, 2023 and 2033
Figure 43: Europe Market Attractiveness, by Country/Sub-region, 2023–2033
Figure 44: Europe Market Value Share (%), by Therapy Type, 2023 and 2033
Figure 45: Europe Market Attractiveness, by Therapy Type, 2023–2033
Figure 46: Europe Market Value Share (%), by Distribution Channel, 2023 and 2033
Figure 47: Europe Market Attractiveness, by Distribution Channel, 2023–2033
Figure 48: Rest of the World Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2023–2033
Figure 49: Rest of the World Market Value Share (%), by Therapy Type, 2023 and 2033
Figure 50: Rest of the World Market Attractiveness, by Therapy Type, 2023–2033
Figure 51: Rest of the World Market Value Share (%), by Distribution Channel, 2023 and 2033
Figure 52: Rest of the World Market Attractiveness, by Distribution Channel, 2023–2033
Figure 53: United Therapeutics Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 54: United Therapeutics Corporation Net sales of Unituxin (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 55: United Therapeutics Corporation Breakdown of Net Sales, by Product, 2022
Figure 56: United Therapeutics Corporation Research and Development Cost (US$ Mn), 2018–2022
Figure 57: United Therapeutics Corporation: SWOT Analysis
Figure 58: MacroGenics, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 59: MacroGenics, Inc. Net sales of Unituxin (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 60: MacroGenics, Inc. Net sales (US$ Mn) by key brands
Figure 61: MacroGenics, Inc. Research and Development Cost (US$ Mn), 2018–2022
Figure 62: MacroGenics, Inc.: SWOT Analysis
Figure 63: APEIRON Biologics AG: SWOT Analysis
Figure 64: Baxter Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2022
Figure 65: Baxter Breakdown of Net Sales (%), by Region, 2022
Figure 66: Baxter pipeline of generic products, 2018–2023
Figure 67: Baxter: SWOT Analysis
Figure 68: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 69: Pfizer Inc. R&D Expenses (US$ Mn), 2018–2022
Figure 70: Pfizer Inc.: SWOT Analysis
Figure 71: Cellectar Biosciences, Inc. Research and Development Cost (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 72: Cellectar Biosciences, Inc.: SWOT Analysis
Figure 73: Bayer Group Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 74: Bayer Group Breakdown of Net Sales (%), by Region, 2022
Figure 75: Bayer Group Breakdown of Net Sales (%), by Business Segment, 2022
Figure 76: Bayer Group: SWOT Analysis
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the pediatric neuroblastoma treatment market?
The global pediatric neuroblastoma treatment market is valued at US$ 2.1 billion in 2023.
What is the projected market value for pediatric neuroblastoma treatment by 2033?
Pediatric neuroblastoma treatment is anticipated to rake in a revenue of US$ 5.3 billion by 2033-end.
At what rate will the demand for pediatric neuroblastoma treatment rise?
Worldwide pediatric neuroblastoma treatment demand is set to rise at an impressive 9.7% CAGR through 2033.
What is the most effective treatment for neuroblastoma?
Chemotherapy is the most widely used and effective treatment for neuroblastoma.
Which key companies are active in the pediatric neuroblastoma treatment industry?
Bayer AG, Pfizer Inc., APEIRON Biologics AG, Baxter, and United Therapeutics Corporation are leading pediatric neuroblastoma treatment providers.
Pediatric Neuroblastoma Treatment Market